Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|August 1, 2017
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyDavid E Cohn, Michael W Sill, Joan L Walker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Floor J Backes, Debra L Richardson, Georgia A McCann, et al.
Gynecologic Oncology|February 15, 2011
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerDavid M O'Malley, Debra L Richardson, Patrick S Rheaume, et al.
Clinical Pharmacology in Drug Development|November 16, 2022
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid TumorsXiaofei Zhou, Debra L Richardson, Afshin Dowlati, et al.
JCO Precision Oncology|October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian CancerLinda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Journal for Immunotherapy of Cancer|January 12, 2025
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancerNehal J Lakhani, Daphne Stewart, Debra L Richardson, et al.
Gynecologic Oncology|July 2, 2025
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIOMelissa M Hardesty, Thomas C Krivak, Gail S Wright, et al.
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Cancer|January 3, 2025
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancersDevalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, et al.
Gynecologic Oncology|June 11, 2022
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumabMelissa M Hardesty, Thomas C Krivak, Gail S Wright, et al.
Pageof 7